✦ LIBER ✦

Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in japanese patients with early Breast Cancer

✍ Scribed by Keiichiro Tada; Yoshinori Ito; Shunji Takahashi; Kohtaro lijima; Yumi Miyagi; Seiichiro Nishimura; Kaoru Takahashi; Masujiro Makita; Takuji Iwase; Masataka Yoshimoto; Fujio Kasumi

Book ID: 111854261
Publisher: Springer Japan
Year: 2006
Tongue: English
Weight: 444 KB
Volume: 13
Category: Article
ISSN: 1340-6868
DOI: 10.2325/jbcs.13.279

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mortality during adjuvant treatment of e

Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil

✍ Marco Colleoni; Karen N Price; Monica Castiglione-Gertsch; Richard D Gelber; Ala 📂 Article 📅 1999 🏛 The Lancet 🌐 English ⚖ 37 KB

On the safety of perioperative adjuvant

On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer

📂 Article 📅 1988 🏛 Elsevier Science ⚖ 409 KB

Acquired protein C deficiency in patient

Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil

✍ Stephen E. Feffer; Linda S. Carmosino; Robin L. Fox 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 529 KB

Randomized trial of cyclophosphamide, ep

Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan

✍ Morihiko Kimura; Takeshi Tominaga; Yuichi Takatsuka; Masakazu Toi; Rikiya Abe; H 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 224 KB

Comparison of melphalan with cyclophosph

Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer

✍ Harvey S. Brodovsky; Madeline Bauer; John Horton; Paul J. Elson 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 718 KB

Vincristine, doxorubicin and mitomycin (

Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF)

✍ Sharon K. Shipp; Hyman B. Muss; Mary Alice Westrick; M. Robert Cooper; V. Jackso 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 383 KB

Thirty-six evaluable patients with advanced breast cancer who had failed prior CMF therapy [15 (42%) as adjuvant treatment and 21 (58%) for advanced disease] were treated with a combination of vincristine, doxorubicin, and mitomycin (VAM). There was one CR and 10 PR, giving a response rate of 31% (P